Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study ProtocolCryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung CancerVaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic SyndromeAutologous and Allogenic Transplantation With Campath-1H for T-Cell LymphomaA Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer PatientsRandomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic CancerMelphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple MyelomaCombination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral RetinoblastomaA Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate CancerTopotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem GliomaVaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's LymphomaMobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma PatientsMobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma PatientsMitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous LeukemiaBiological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous TreatmentVaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV MelanomaVaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryVaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV MelanomaVaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaVaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for MelanomaVaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal CancerLiposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's LymphomaHER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung CancerPANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced CancerCombination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue SarcomaVaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's LymphomaS9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCombination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced NeuroblastomaInterleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV MelanomaCyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic MelanomaRadiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell TumorUARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation ChemotherapyCombination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's DiseaseChemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's DiseaseAmifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid TumorsBiological Therapy in Treating Women With Metastatic Breast CancerMonoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal CancerChemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple MyelomaVaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
P4844
Sargramostim (GM-CSF) for induction of remission in Crohn's diseaseSargramostim (GM-CSF) for induction of remission in Crohn's diseaseSargramostim for active Crohn's diseaseA comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppressionPerioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgeryIpilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trialPhase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study.Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma.Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy.Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.The role of sargramostim (rhGM-CSF) as immunotherapy.A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study.Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials.Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma.Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim.Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.Drug formulary review process for sargramostim and filgrastim: focus on analysis of adverse drug reactions.Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells.Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy.Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein IntolerancePhase I trial of sargramostim in pediatric Crohn's disease.Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia.Marginal keratitis associated with administration of filgrastim and sargramostim in a healthy peripheral blood progenitor cell donor.Fulminant CNS perivascular lymphocytic proliferation: association with sargramostim, a hematopoietic growth factor.Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment.Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy.Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.Sargramostim in patients with Crohn's disease: results of a phase 1-2 study.Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning.
P921
Q59494137-4891d570-4d99-adcc-2600-77c29b3393bdQ61978903-7B1C162B-EA99-42D9-946A-B2F85BEBE0EFQ61978949-4218FE20-75C8-4B3B-B025-1CC3CCBF9679Q61979949-54218779-F600-466E-8E86-617E9B68E83EQ61980115-936BFF0E-337C-4D86-95D3-7491229437C6Q61981344-88614C38-24A1-4254-86D1-DF44BBBA3AAAQ62025849-764B3CE0-DF3F-4EE5-A3B5-70E907ED510EQ62105018-1A058FC1-343E-449C-A0BA-735766931C97Q62105297-D975DE10-0CD7-44DF-BDDB-29F53822A2C3Q62105424-29DDF22F-4EA3-4E35-B38D-B9CC29074977Q62105617-4276D9C3-D37B-49D6-AC93-1D00CCA5B05FQ62105834-85D0313D-4902-4563-B01F-8CEC21A435CDQ62105945-C885C9EC-2CE3-49B6-9BF6-CB9CEF44783EQ62105958-C9B8F858-A03B-4F5B-9A20-09F8F57ACF9DQ62110016-58FCC8EF-F004-4B83-A360-BB666B9D1962Q62110078-F541D1E5-D1E8-489E-8B97-F1698ACB1DBFQ62110080-A44F1D3E-E562-40CD-977D-01185C0F2AB9Q62110081-449AE5D9-AD0D-4B93-BA2D-A5D3DA325675Q62110082-9E843950-DC2D-4CCC-A746-28D4ABD658AAQ62110090-DDE66A2D-E2F0-4595-97C0-C9281E0F5EC9Q62110094-7F3FE9FE-D291-4378-990F-93170C85F5D3Q62110106-0104E5F6-832E-48BF-8DE1-067296CE87B7Q62110121-B5C3954C-7F37-4FE3-A361-6BDD412BED9DQ62110192-DEAED244-051B-4833-8126-DEA19E2D0609Q62110225-DF4F87E9-3B7C-405F-AD56-C250BBB10352Q62110529-E33A6100-15AA-4FBA-A758-87573A1AD0EDQ62110565-6E39C9D8-01FA-454F-974C-C96671E33415Q62110626-5E0A4DB1-C3AE-4C63-925C-5A5071241D01Q62110672-FC2EFCDC-4CA0-4D58-9066-2BDD6171C25BQ62110677-516F8B41-1D88-4C0A-8D79-A674A23C0A55Q62110689-77C184ED-B8C2-4E28-8636-7C0AA5B2CABCQ62110710-59E8AC96-9B46-42F2-9BC6-385BA7AEE161Q62110903-1AD819BA-31BB-4FE7-87EB-60E086A208E9Q62110933-9EA3D8B4-5A5F-4CE4-967B-EFE704C42E51Q62110941-9FADE5D0-DD07-411B-B48E-2D475F5BF0A4Q62110988-579EEA2B-DE16-4084-8B54-D017607C5E91Q62110998-65EEECA3-2843-42AF-96CC-30C5C941F14AQ62111002-B4DDD1C7-1741-4951-A06B-C3F72882B842Q62111007-3537AE20-E4F0-405A-BFA3-17D54C929784Q62111012-10D4A492-6099-4125-A68C-E238291A06D2
P4844
Q24235068-22A756EB-683E-43D2-910C-0BC579D8EEAFQ24235115-8C534D1D-6514-4B8F-AFD0-C9A0F18DB205Q28252940-2C833C93-ADDE-4B0D-903F-E21DC29A9300Q28277632-9BC6F03C-6446-4F24-9B60-CA490FBAC82FQ28303071-C10F9D24-6CC3-40B1-82C5-6EF132FEF6BBQ30407940-AB464568-4F6D-48E9-8A6E-D6586195AEACQ33367537-6AFD42E5-AF78-42CB-8750-F866874DA1B9Q33406537-DA6D7039-3232-45C0-BF0D-AAC785D8BE06Q33488800-54103907-D8CE-401E-80C4-9F3016BF47A3Q33497695-2BFC450D-672F-4104-9290-220F80C4714DQ34113758-15BD08AB-48ED-4407-9795-750EF340CE2EQ36031518-1ADBEEA2-D585-4C21-A259-C383FD441440Q37015071-003A1AAF-8EA6-4984-91B1-36635C1EF11EQ37223381-15AD280F-4211-4ECD-850E-50AB351A0E4CQ38007115-ED6B3631-7813-46D6-83E9-30C80F6D502EQ38046894-D1057B8B-F943-4FA5-8431-4304CE5E3F26Q38709455-AEF7A5F6-6876-4436-9E86-323361BB513AQ39118074-04246ACC-237B-4AAC-8721-1CE2DDD4BE38Q40234641-7B8BD379-BE18-47DA-B8EF-C82371D47D81Q40331854-12370D70-1449-4723-BC17-21F1CC0D4A47Q40385017-9CC92748-8CF1-4BC9-BDAD-1665F33B6F65Q40600373-3810143B-14DE-4CCD-8763-04F2497BEBB9Q40628003-5356BF29-9BD8-4FD9-AA9E-078B2477F9D9Q40648751-F710BEED-57F5-437E-A204-56411463E5F0Q41009034-5800D8A6-DBD7-4EA9-81BD-DF24045964C5Q42644869-495E0628-F43D-494C-A10E-5F8BE90ABC27Q44070887-8869D3BD-FCCC-415C-9535-32C099AC498FQ44072468-66626557-C44B-4AB2-B2BF-FBE53F46EF44Q44864781-5416482C-9983-428D-A021-18A2ED4F076AQ44957100-2251D014-F169-4DFA-8391-CC7BF2AA3012Q45107966-E25E4358-D69C-479C-9BF6-F7C7BF457BAFQ45977890-9250C6F8-FEFA-456A-97FA-14C10720ECFBQ46593196-2F8B73BA-9621-4E7E-95A4-6DF22955CCADQ48034825-4037EE79-D266-429B-86F4-B363BEBFFB48Q50635378-0E447CFE-86C0-4701-B1D5-37F543B294D8
P921
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Sargramostim
@en
Sargramostim
@it
Sargramostim
@nl
Sargramostim
@sh
Sargramostim
@sr
Sargramostim
@vi
sargramostim
@fr
sargramostim
@nn
سارغراموستيم
@ar
沙格司亭
@zh
type
label
Sargramostim
@en
Sargramostim
@it
Sargramostim
@nl
Sargramostim
@sh
Sargramostim
@sr
Sargramostim
@vi
sargramostim
@fr
sargramostim
@nn
سارغراموستيم
@ar
沙格司亭
@zh
altLabel
B1 61.012
@en
Leukine
@en
recombinant GM-CSF
@en
prefLabel
Sargramostim
@en
Sargramostim
@it
Sargramostim
@nl
Sargramostim
@sh
Sargramostim
@sr
Sargramostim
@vi
sargramostim
@fr
sargramostim
@nn
سارغراموستيم
@ar
沙格司亭
@zh
P2175
P31
P486
P592
P6366
P1417
science/sargramostim
P2115
N0000147658
P267
P2868
P3345
P486
P592
CHEMBL1201670
P6366
2776186052
P652
5TAA004E22